Exelixis UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, everybody. Welcome to UBS Global Biopharma Conference in London. My name is Ash Verma. I cover SMID-Cap Biotech and Spec Pharma. I am really excited to have Exelixis as the next company. I have Andrew Peters, who is the SVP of Strategy and Investor Relations. Thank you, Andrew, for joining us.
Yeah, thank you for the invite.
Yeah, Exelixis has been a pretty incredible story, just looking at the stock chart. I mean, what a turnaround you've had, going from back when you settled on CABOMETYX and then Zanza, and sort of building out the pipeline. Maybe if you can just highlight a couple of key topics in terms of some of the recent updates that you've had from the third quarter earnings, and then we can take it from there.
Yeah, great. Thanks again for the invite. Happy to be here as an alumnus of UBS myself. It is always good to be on stage in this seat versus that seat. As a reminder, I am going to be making some forward-looking statements today, so please see relevant disclosures around risks to our business in our filings with the SEC. Yeah, it is a really exciting time to be at Exelixis. It is kind of that pivot point or turning point for the company as we are transitioning from a single-product company with CABOMETYX to now a multi-franchise company with zanzalintinib in our potential approval and PDUFA date early next year. One of the things we say all the time, biotech, biopharma is a really tough business. Finding one successful franchise is hard.
Doing it a second time is even more difficult, and that's something that I really think we internalize and are particularly proud of and kind of all the work and excitement that we have internally. So, third quarter call, really it's kind of about two things, the Cabo business continuing to kind of hum along, and then Zanza development, Zanza pre-commercial activity, and then kind of our internal efforts around early pipeline and expense management, expense discipline, and kind of this through line that we run Exelixis like a business and not a biotech, and that's something that we really take to heart and try and do. So, excited times, but our focus is just on execution. We're going to keep our head down and keep going.
Yeah, that's great. So maybe I'll spend a little bit of a few questions on CABOMETYX first. So, I think there has been a few datasets that have come out, particularly the LITESPARK-011 study, and some of the feedback that we've heard from physicians is that, as that regimen starts to get used in more second line, Cabo moves more to earlier line. Is that sort of similar to the dynamic that you're experiencing as well? And just from your vantage point, if you can talk about what's sort of the flow of patients that you would benefit out of this.
Yeah. So I think you're referring to the LITESPARK-011 data that came out at ESMO earlier this year. And taking a step back, I think ESMO was great in a sense that there was a lot of data coming out in RCC, and it's kind of the market leaders in RCC. It's heartening to see a lot of interest in the space and a lot of kind of growing just combinations, modalities, all of that stuff. It's something that we're certainly focused on and paying attention to. So great to see. Some kind of learnings there, I guess, before I talk about LITESPARK-011, one of the things in the broader RCC space that we certainly focus on is LITESPARK-012 and the failure there. And what that really does is it opens the door for opportunities for Exelixis to invest in the front line.
So that's something, kind of an area to certainly stay tuned over the next several months as we think about how to kind of implement a strategy there. But your question on LITESPARK-011 and kind of the second line dynamic, really the full dataset that read out at ESMO was really kind of as expected. They saw a PFS benefit, but didn't see a statistically significant survival advantage. And it kind of comes down to one of those age-old questions in oncology where, is it better to sequence or is it better to combine? Historically, the way that you answer that question is overall survival. Because if you take a look at, say, CABOMETYX or a TKI on its own in second line, and then belzutifan on its own in third line, you're 10, 11 months, five, six months.
The totality, the absolute PFS of the sequence approach is actually a little bit longer than the combined approach, then you layer on the tox and tolerability issues and all of that. It becomes a real kind of question for patients and physicians in a conversation to have, especially in the context of no overall survival. That is some of the kind of market backdrop that we expect. The second part is certainly the case where we talked about, if those patients and physicians are likely to get LEN/BEL second line, means they most likely will not get LEN first line. That kind of first line market share that we are continuing to fight for every single day in the market, that should probably benefit us. Again, as all of the data continue to kind of stream out of ESMO, not a lot really changed.
We will probably see some incremental share in first line, depending off if we lose some share second line. It is kind of that dynamic is what we are paying attention to.
All right. Okay. If I can just follow up, that is an interesting nugget that you could pursue more opportunities in the first line. I mean, is it more for Cabo or some early stage pipeline?
No, no, Zanza. I guess big picture, I mean, the way that we are thinking about it is we have the seven pivotal studies with Zanza right now. We call it wave one. The totality of those opportunities, we think, not only can let us kind of grow through Cabo, but grow much better than Cabo. Then we are layering on the second wave of Zanza opportunities, which we think have the potential to be much bigger. I would certainly lump that frontline RCC study that we are kind of putting the finishing touches on, so to speak, as one of the key anchor points of that second wave of Zanza.
Got it. Okay. Perfect. I know there's been some competitor update on the HIF-2α, casdatifan didn't really generate the competitive dataset in second line RCC. Just like your thoughts on that, curious to see, they have a first line study that's reading out in 2028. Just curious from your perspective, is there could be sort of like a revival of this thesis that is more competition?
Yeah. The HIF space is certainly one we're focused on. Obviously, we have two pivotal studies that Merck is running with Zanza and BELZ. Totality of the data, we tend to see those two molecules as probably more similar than different, with Zanza as the kind of best-in-class TKI choice. I mean, our perspective on the evolution of how RCC patients will be treated in the future is that Cabo's the TKI of choice for the 2020s, and Zanza will be the TKI of choice for the 2030s.
That's a dynamic that, again, is going to kind of flow through, one, these wave one studies, but the wave two studies as well, as we think about not necessarily kind of how patients are managed and what their journey looks like today from a first line, second line, third line perspective, but the way we approach development is, how are patients going to be treated? What is their journey like with RCC going to be like in 2032, 2033, where more patients are likely to get adjuvant pembro? So that frontline opportunity set is just functionally different than, say, how they're managed today or how they were managed two years ago. So that kind of dynamic changes.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
